Truvestments Capital’s Adicet Bio ACET Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-16
Closed -$592 225
2024
Q1
$592 Hold
16
﹤0.01% 667
2023
Q4
$476 Sell
16
-27
-63% -$589 ﹤0.01% 742
2023
Q3
$947 Buy
43
+16
+59% +$565 ﹤0.01% 624
2023
Q2
$1.07K Hold
27
﹤0.01% 629
2023
Q1
$2.53K Buy
+27
New +$3.39K ﹤0.01% 564

Other funds holding ACET

Truvestments Capital's ACET Position: Q2 2024 in Review

Truvestments Capital sold out of Adicet Bio (ACET) in Q2 2024, closing a stake of 16 shares — an estimated $592 sold.

Truvestments Capital first reported a position in ACET in Q1 2023 and held it in 5 quarters. The position peaked at $2.53K in Q1 2023. 86 funds tracked by Wall St. Rank hold ACET as of Q2 2024.

  • Truvestments Capital reported no remaining Adicet Bio position as of Q2 2024 after selling out during the quarter.
  • Truvestments Capital sold 16 Adicet Bio shares in Q2 2024, an estimated $592.
  • Truvestments Capital first reported a position in Adicet Bio in Q1 2023 and held it in 5 quarters.
  • Truvestments Capital's Adicet Bio position peaked at $2.53K in Q1 2023.
  • 86 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2024.

Based on Truvestments Capital's 13F filing for Q2 2024, filed 14 Aug 2024.